Treatment for patients with Hodgkin’s lymphoma is one of the success stories of modern medicine. A once uniformly fatal disorder is now curable, even in an advanced stage, in the great majority of patients. In fact, particularly in limited-stage Hodgkin’s lymphoma, much of the therapeutic focus is on maintaining the high probability of cure while reducing the incidence of toxic effects. How little therapy can we give without losing efficacy? For patients with advanced-stage, high-risk disease, debates regarding the best currently available approach have centered on the “old standard” ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen,1 the very intensive escalated . . .
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
This editorial was published on July 13, 2022, at NEJM.org.
Print Subscriber? Activate your online access.